TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Cross Over Trial of Two Treatments for OSA in Veterans With PTSD
Brief Summary: Sleep disturbances are cardinal features of Veterans with post traumatic stress disorder (PTSD). In particular, obstructive sleep apnea is reported to occur more frequently in patients with PTSD compared to those without PTSD and contribute to worsening cognitive and behavioral functions. Continuous positive airway pressure (CPAP) is considered the treatment of choice for OSA but adherence to CPAP in Veterans with PTSD is poor compared to the general population. The proposed study aims at comparing the efficacy, tolerability, and adherence of oral appliances-an alternative therapy to OSA- to CPAP. The study is instrumental in identifying the optimal OSA therapy for Veterans with PTSD and the OSA phenotype that would predict oral appliance response


Options:
A: Arm Label: CPAP First, MAD; Type: ACTIVE_COMPARATOR; Interventions: Device: CPAP, Device: MAD | Arm Label: MAD First, CPAP; Type: EXPERIMENTAL; Interventions: Device: CPAP, Device: MAD | Intervention Type: DEVICE; Name: CPAP; Assigned to Arm(s): CPAP First, MAD, MAD First, CPAP | Intervention Type: DEVICE; Name: MAD; Assigned to Arm(s): CPAP First, MAD, MAD First, CPAP
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: CPAP | Intervention Type: DEVICE; Name: CPAP; Assigned to Arm(s): 2
C: Arm Label: Sleep Unit group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Primary Care group; Type: EXPERIMENTAL; Interventions: Other: Clinical follow up by general practitioners in primary care | Intervention Type: OTHER; Name: Clinical follow up by general practitioners in primary care; Assigned to Arm(s): Primary Care group
D: Arm Label: TLC-CPAP; Type: EXPERIMENTAL; Interventions: Device: Telecommunications system | Arm Label: TLC-Control; Type: PLACEBO_COMPARATOR; Interventions: Other: TLC-Control | Intervention Type: DEVICE; Name: Telecommunications system; Assigned to Arm(s): TLC-CPAP | Intervention Type: OTHER; Name: TLC-Control; Assigned to Arm(s): TLC-Control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia
Brief Summary: The primary objective of this study is to evaluate the effect of the addition of idelalisib (formerly GS-1101) to bendamustine + rituximab (BR) on progression-free survival (PFS) in participants with previously treated chronic lymphocytic leukemia (CLL)


Options:
A: Arm Label: Idelalisib & Ofatumumab; Type: EXPERIMENTAL; Interventions: Drug: Idelalisib, Drug: Ofatumumab | Intervention Type: DRUG; Name: Idelalisib; Assigned to Arm(s): Idelalisib & Ofatumumab | Intervention Type: DRUG; Name: Ofatumumab; Assigned to Arm(s): Idelalisib & Ofatumumab
B: Arm Label: Idelalisib+bendamustine+rituximab; Type: EXPERIMENTAL; Interventions: Drug: Idelalisib, Drug: Rituximab, Drug: Bendamustine | Arm Label: Placebo to match idelalisib+bendamustine+rituximab; Type: PLACEBO_COMPARATOR; Interventions: Drug: Rituximab, Drug: Bendamustine, Drug: Placebo to match idelalisib | Intervention Type: DRUG; Name: Idelalisib; Assigned to Arm(s): Idelalisib+bendamustine+rituximab | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Idelalisib+bendamustine+rituximab, Placebo to match idelalisib+bendamustine+rituximab | Intervention Type: DRUG; Name: Bendamustine; Assigned to Arm(s): Idelalisib+bendamustine+rituximab, Placebo to match idelalisib+bendamustine+rituximab | Intervention Type: DRUG; Name: Placebo to match idelalisib; Assigned to Arm(s): Placebo to match idelalisib+bendamustine+rituximab
C: Arm Label: Fludarabine + Campath-1H; Type: EXPERIMENTAL; Interventions: Biological: alemtuzumab, Drug: fludarabine phosphate | Intervention Type: BIOLOGICAL; Name: alemtuzumab; Assigned to Arm(s): Fludarabine + Campath-1H | Intervention Type: DRUG; Name: fludarabine phosphate; Assigned to Arm(s): Fludarabine + Campath-1H
D: Arm Label: Rituximab + PCI-32765; Type: EXPERIMENTAL; Interventions: Drug: Rituximab, Drug: PCI-32765 | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Rituximab + PCI-32765 | Intervention Type: DRUG; Name: PCI-32765; Assigned to Arm(s): Rituximab + PCI-32765

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Four-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of AF-219 in Female Subjects With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
Brief Summary: The purpose of this study is to assess the efficacy of gefapixant (AF-219/MK-7264) in female participants with moderate to severe pain associated with interstitial cystitis/bladder pain syndrome (IC/BPS) after 4 weeks of treatment.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Device: Placebo | Arm Label: Low energy shock wave; Type: EXPERIMENTAL; Interventions: Device: Low energy shock wave | Intervention Type: DEVICE; Name: Low energy shock wave; Assigned to Arm(s): Low energy shock wave | Intervention Type: DEVICE; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Global Therapeutic Massage (GTM); Type: PLACEBO_COMPARATOR; Interventions: Other: Global Therapeutic Massage (GTM) | Arm Label: Myofascial physical therapy (MPT); Type: ACTIVE_COMPARATOR; Interventions: Other: Myofascial physical therapy (MPT) | Intervention Type: OTHER; Name: Global Therapeutic Massage (GTM); Assigned to Arm(s): Global Therapeutic Massage (GTM) | Intervention Type: OTHER; Name: Myofascial physical therapy (MPT); Assigned to Arm(s): Myofascial physical therapy (MPT)
C: Arm Label: Manual therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Manual therapy | Arm Label: Dry needling & manual therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Manual therapy, Procedure: Trigger point dry needling | Intervention Type: PROCEDURE; Name: Manual therapy; Assigned to Arm(s): Dry needling & manual therapy, Manual therapy | Intervention Type: PROCEDURE; Name: Trigger point dry needling; Assigned to Arm(s): Dry needling & manual therapy
D: Arm Label: Gefapixant; Type: EXPERIMENTAL; Interventions: Drug: Gefapixant | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Gefapixant; Assigned to Arm(s): Gefapixant | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double Blinded, Randomized Study Comparing Rituximab Induction Therapy Followed by Glatiramer Acetate Therapy to Glatiramer Acetate Monotherapy in Patients With Relapsing Forms of Multiple Sclerosis
Brief Summary: The purpose of this study is (1) to determine if rituximab induction therapy followed by glatiramer acetate (GA) is substantially superior to placebo rituximab induction followed by GA for the treatment of clinically isolated syndrome (CIS) or relapsing forms of multiple sclerosis (RMS).


Options:
A: Arm Label: (Placebo and) Glatiramer Acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glatiramer Acetate, Other: Placebo | Arm Label: Rituximab and Glatiramer Acetate (R-GA); Type: EXPERIMENTAL; Interventions: Drug: Rituximab, Drug: Glatiramer Acetate | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Rituximab and Glatiramer Acetate (R-GA) | Intervention Type: DRUG; Name: Glatiramer Acetate; Assigned to Arm(s): (Placebo and) Glatiramer Acetate, Rituximab and Glatiramer Acetate (R-GA) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): (Placebo and) Glatiramer Acetate
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: rituximab | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: rituximab; Assigned to Arm(s): 1
C: Arm Label: Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Rituximab | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Rituximab
D: Arm Label: Cohort; Type: N/A; Interventions: Biological: Rituximab | Intervention Type: BIOLOGICAL; Name: Rituximab; Assigned to Arm(s): Cohort

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Striving to Quit: First Breath Tobacco Cessation Research
Brief Summary: This study is designed to test the hypotheses that incentives can increase both participation in smoking cessation treatment and resulting cessation rates, when they are offered to Medicaid BadgerCare Plus pregnant smokers.


Options:
A: Arm Label: Group commitment contracts; Type: EXPERIMENTAL; Interventions: Behavioral: Group commitment contract, Behavioral: Smoking cessation education and counseling | Arm Label: Education and counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Smoking cessation education and counseling | Intervention Type: BEHAVIORAL; Name: Group commitment contract; Assigned to Arm(s): Group commitment contracts | Intervention Type: BEHAVIORAL; Name: Smoking cessation education and counseling; Assigned to Arm(s): Education and counseling, Group commitment contracts
B: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Counseling from WTQL | Arm Label: Incentive; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling from WTQL, Other: Financial incentive to participate | Intervention Type: BEHAVIORAL; Name: Counseling from WTQL; Assigned to Arm(s): Control, Incentive | Intervention Type: OTHER; Name: Financial incentive to participate; Assigned to Arm(s): Incentive
C: Arm Label: Usual care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Usual care | Arm Label: Lung Age; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lung age | Arm Label: Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Contingency Management | Arm Label: Lung age + Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lung age + Contingency Management | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual care | Intervention Type: BEHAVIORAL; Name: Lung age; Assigned to Arm(s): Lung Age | Intervention Type: BEHAVIORAL; Name: Contingency Management; Assigned to Arm(s): Contingency Management | Intervention Type: BEHAVIORAL; Name: Lung age + Contingency Management; Assigned to Arm(s): Lung age + Contingency Management
D: Arm Label: Treatment incentives; Type: EXPERIMENTAL; Interventions: Behavioral: Incentives for abstinence and treatment engagement | Arm Label: Attendance incentive; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Attendance incentive | Intervention Type: BEHAVIORAL; Name: Incentives for abstinence and treatment engagement; Assigned to Arm(s): Treatment incentives | Intervention Type: BEHAVIORAL; Name: Attendance incentive; Assigned to Arm(s): Attendance incentive

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Hypoallergenicity of an Amino Acid-Based Infant Formula
Brief Summary: The primary objective of this clinical trial is to determine whether a new amino acid-based formula is hypoallergenic as defined by the American Academy of Pediatrics (2000), demonstrating that the test formula does not provoke allergenic activity in 90% of infants or children with confirmed cow's milk allergy (CMA) with 95% confidence as compared to a commercially available hypoallergenic formula.


Options:
A: Arm Label: New Amino Acid formula; Type: EXPERIMENTAL; Interventions: Other: Amino Acid formula | Arm Label: Control formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Commercially available Amino Acid Formula | Intervention Type: OTHER; Name: Amino Acid formula; Assigned to Arm(s): New Amino Acid formula | Intervention Type: OTHER; Name: Commercially available Amino Acid Formula; Assigned to Arm(s): Control formula
B: Arm Label: New Neocate; Type: EXPERIMENTAL; Interventions: Dietary Supplement: new Neocate | Arm Label: Neocate Infant; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Neocate Infant | Intervention Type: DIETARY_SUPPLEMENT; Name: Neocate Infant; Assigned to Arm(s): Neocate Infant | Intervention Type: DIETARY_SUPPLEMENT; Name: new Neocate; Assigned to Arm(s): New Neocate
C: Arm Label: Cysteine; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Parenteral cysteine-HCl supplementation | Arm Label: No-cysteine placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo - added premasol | Intervention Type: DIETARY_SUPPLEMENT; Name: Parenteral cysteine-HCl supplementation; Assigned to Arm(s): Cysteine | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo - added premasol; Assigned to Arm(s): No-cysteine placebo
D: Arm Label: Isoleucine; Type: ACTIVE_COMPARATOR; Interventions: Other: ORS + Isoleucine | Arm Label: ORS without Isoleucine; Type: PLACEBO_COMPARATOR; Interventions: Other: ORS without Isoleucine | Intervention Type: OTHER; Name: ORS + Isoleucine; Assigned to Arm(s): Isoleucine | Intervention Type: OTHER; Name: ORS without Isoleucine; Assigned to Arm(s): ORS without Isoleucine

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: What is the best medication for hormonal stimulation in cycles with high intra-uterine insemination: tablets of Clomifen (5 days) followed by tablets of Ethinyl Estradiol (5 days) or daily injections with Human Menopausal Gonadotropin (Menopur)?


Options:
A: Arm Label: Tablets; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clomifen, Ethinyl Estradiol | Arm Label: human menopausal gonadotropins; Type: ACTIVE_COMPARATOR; Interventions: Drug: Menotropins | Intervention Type: DRUG; Name: Clomifen, Ethinyl Estradiol; Assigned to Arm(s): Tablets | Intervention Type: DRUG; Name: Menotropins; Assigned to Arm(s): human menopausal gonadotropins
B: Arm Label: Extended letrozole regimen; Type: EXPERIMENTAL; Interventions: Drug: Extended letrozole regimen | Arm Label: Clomiphene citrate regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clomiphene citrate regimen | Intervention Type: DRUG; Name: Extended letrozole regimen; Assigned to Arm(s): Extended letrozole regimen | Intervention Type: DRUG; Name: Clomiphene citrate regimen; Assigned to Arm(s): Clomiphene citrate regimen
C: Arm Label: HP-hMG; Type: ACTIVE_COMPARATOR; Interventions: Drug: Meropur 150 a day | Arm Label: rFSH plus rLH; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gonal-f 150 plus Luveris 150 | Intervention Type: DRUG; Name: Meropur 150 a day; Assigned to Arm(s): HP-hMG | Intervention Type: DRUG; Name: Gonal-f 150 plus Luveris 150; Assigned to Arm(s): rFSH plus rLH
D: Arm Label: Aromatase Inhibitors (AI); Type: ACTIVE_COMPARATOR; Interventions: Drug: Letrozole (aromatase inhibitor) | Arm Label: Clomiphene Citrate (CC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Clomiphene Citrate | Arm Label: Follicle Stimulating Hormone (FSH); Type: ACTIVE_COMPARATOR; Interventions: Drug: Follicle Stimulating Hormone (gonadotropin) | Intervention Type: DRUG; Name: Letrozole (aromatase inhibitor); Assigned to Arm(s): Aromatase Inhibitors (AI) | Intervention Type: DRUG; Name: Clomiphene Citrate; Assigned to Arm(s): Clomiphene Citrate (CC) | Intervention Type: DRUG; Name: Follicle Stimulating Hormone (gonadotropin); Assigned to Arm(s): Follicle Stimulating Hormone (FSH)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Interest of Systematic Tracking of Dementia Cases in Nursing Homes: Analysing the Contribution of MultiDisciplinary Team Meeting (MDTM) in Alzheimer's Disease and Related Diseases
Brief Summary: Introduction: Epidemiological data show that in France only half of patients with Alzheimer disease are currently diagnosed in the general population. The absence of early diagnosis of dementia reduces the opportunities of patients to receive optimal care. One of the consequences of undiagnosed dementia is inadequate use of emergency care units.

The main objective: The main aim of this study is to evaluate the impact of a systematic case-finding procedure of dementia cases in nursing homes through a MDTM on the rate of hospitalization in emergency care units.

Secondary objectives:

To assess the impact of systematic tracking of dementia cases on the:

* Quantity and quality of drug-prescription
* Appropriateness of hospitalizations
* Prevalence of neuropsychiatric symptoms
* Dependency
* Quality of life
* Burden of nursing staff working conditions
* Planning of specific therapeutic measures
* Overall health care costs


Options:
A: Arm Label: Intervention group; Type: OTHER; Interventions: Other: MultiDisciplinary Team Meetings (MDTM) | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: MultiDisciplinary Team Meetings (MDTM); Assigned to Arm(s): Intervention group
B: Arm Label: Fall QI; Type: EXPERIMENTAL; Interventions: Behavioral: Falls QI | Arm Label: Connect & Falls QI; Type: EXPERIMENTAL; Interventions: Behavioral: Connect | Intervention Type: BEHAVIORAL; Name: Falls QI; Assigned to Arm(s): Fall QI | Intervention Type: BEHAVIORAL; Name: Connect; Assigned to Arm(s): Connect & Falls QI
C: Arm Label: INH (Intervention Nursing Homes); Type: EXPERIMENTAL; Interventions: Other: TIME | Arm Label: CNH (Control Nursing Homes); Type: ACTIVE_COMPARATOR; Interventions: Other: Education-only intervention | Intervention Type: OTHER; Name: TIME; Assigned to Arm(s): INH (Intervention Nursing Homes) | Intervention Type: OTHER; Name: Education-only intervention; Assigned to Arm(s): CNH (Control Nursing Homes)
D: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: ACP+ programme | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ACP+ programme; Assigned to Arm(s): Intervention group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Post Market Study - "European Observational Study of the Sapheon™ Closure System for the Definitive Treatment of Incompetent Great Saphenous Veins: A Prospective Single Arm Multicenter Clinical Observational Study"
Brief Summary: The primary objective for this clinical study is to assess the role of the CE Marked Sapheon Closure System in closure of incompetent great saphenous veins "GSV" in a routine clinical setting.


Options:
A: Arm Label: Conventional Surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Conventional Surgery | Arm Label: Radiofrequency Ablation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Radiofrequency Ablation | Intervention Type: PROCEDURE; Name: Conventional Surgery; Assigned to Arm(s): Conventional Surgery | Intervention Type: PROCEDURE; Name: Radiofrequency Ablation; Assigned to Arm(s): Radiofrequency Ablation
B: Arm Label: CE Marked Sapheon Closure System in GSV; Type: EXPERIMENTAL; Interventions: Device: CE Marked Sapheon Closure System | Intervention Type: DEVICE; Name: CE Marked Sapheon Closure System; Assigned to Arm(s): CE Marked Sapheon Closure System in GSV
C: Arm Label: High ligation and stripping (surgery); Type: N/A; Interventions: N/A | Arm Label: Foam sclerotherapy; Type: N/A; Interventions: N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: crossectomy and short stripping | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: ultrasound guided sclerotherapy with foam | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: endovenous laser therapy | Intervention Type: PROCEDURE; Name: crossectomy and short stripping; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: ultrasound guided sclerotherapy with foam; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: endovenous laser therapy; Assigned to Arm(s): 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Feasibility, Safety and Efficacy of RIPC for Symptomatic Intracranial Arterial Stenosis in Octogenarians
Brief Summary: Making a limb transiently ischemic induces ischemic tolerance in distant organs such as the heart. This study aims to evaluate the feasibility, safety and initial efficacy of using briefly repetitive bilateral limb ischemic preconditioning (BLIPC) to protect the brain in octogenarians with symptomatic intracranial arterial stenosis.


Options:
A: Intervention Type: PROCEDURE; Name: remote ischemic preconditioning; Assigned to Arm(s): N/A
B: Arm Label: bilateral limb ischemic preconditioning (BLIPC); Type: EXPERIMENTAL; Interventions: Device: bilateral limb ischemic preconditioning (Doctormate, IPC-906X) | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: bilateral limb ischemic preconditioning (Doctormate, IPC-906X); Assigned to Arm(s): bilateral limb ischemic preconditioning (BLIPC)
C: Arm Label: remote ischemic preconditioning; Type: EXPERIMENTAL; Interventions: Procedure: remote ischemic preconditioning | Arm Label: placebo remote ischemic preconditioning; Type: SHAM_COMPARATOR; Interventions: Procedure: sham remote ischemic preconditioning | Intervention Type: PROCEDURE; Name: remote ischemic preconditioning; Assigned to Arm(s): remote ischemic preconditioning | Intervention Type: PROCEDURE; Name: sham remote ischemic preconditioning; Assigned to Arm(s): placebo remote ischemic preconditioning
D: Arm Label: Trevo Thrombectomy Procedure; Type: EXPERIMENTAL; Interventions: Device: Trevo Thrombectomy Procedure, Other: Medical Management | Arm Label: Medical Management; Type: ACTIVE_COMPARATOR; Interventions: Other: Medical Management | Intervention Type: DEVICE; Name: Trevo Thrombectomy Procedure; Assigned to Arm(s): Trevo Thrombectomy Procedure | Intervention Type: OTHER; Name: Medical Management; Assigned to Arm(s): Medical Management, Trevo Thrombectomy Procedure

Answer: B